|
SLC35F5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.28879999958554E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.018910E-04 |
| Normal-vs-Stage2 |
7.95760000000811E-05 |
| Normal-vs-Stage3 |
7.82850000047297E-07 |
| Normal-vs-Stage4 |
8.88039641822047E-11 |
| Stage1-vs-Stage2 |
4.745800E-01 |
| Stage1-vs-Stage3 |
9.893900E-02 |
| Stage1-vs-Stage4 |
3.6847000000062E-05 |
| Stage2-vs-Stage3 |
5.301400E-01 |
| Stage2-vs-Stage4 |
9.541300E-03 |
| Stage3-vs-Stage4 |
3.318300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.0088000004318E-07 |
| Normal-vs-AfricanAmerican |
1.075690E-03 |
| Normal-vs-Asian |
2.13710000029899E-07 |
| Caucasian-vs-AfricanAmerican |
9.039200E-01 |
| Caucasian-vs-Asian |
1.417160E-01 |
| AfricanAmerican-vs-Asian |
4.294000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.58537999999098E-05 |
| Normal-vs-Female |
6.77740000010196E-07 |
| Male-vs-Female |
6.703600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.428500E-04 |
| Normal-vs-Age(41-60Yrs) |
5.39350000217098E-08 |
| Normal-vs-Age(61-80Yrs) |
3.44080000047597E-07 |
| Normal-vs-Age(81-100Yrs) |
4.667400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.575800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.193700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.188000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.202400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.462000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.610200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.432500E-04 |
| Classical-VS-Follicular |
5.006300E-02 |
| Classical-VS-Other |
4.255800E-01 |
| Classical-VS-Normal |
1.02400000001612E-06 |
| Tall-VS-Follicular |
9.64390000000037E-05 |
| Tall-VS-Other |
2.350200E-01 |
| Tall-VS-Normal |
6.34699959256579E-10 |
| Follicular-VS-Other |
6.619900E-02 |
| Follicular-VS-Normal |
1.388240E-02 |
| Other-VS-Normal |
3.556700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.80181999999141E-05 |
| Normal-vs-N1 |
1.5499599999913E-05 |
| N0-vs-N1 |
2.327600E-01 |
|
|
